Therapy

ImmunoGen Introduces Taxane-Based Tumor-Activated Prodrug Platform

Published in Cancer Weekly, December 11th, 2001

ImmunoGen, Inc., (IMGN) has reported that data from its taxane-based Tumor-Activated Prodrug (TAP) platform showed exceptional antitumor activity in mice. Results were presented at the 2001 American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC).

"Broadening our TAP technology is an important element of our long-term strategy," said Mitchel Sayare, PhD, chairman and CEO of ImmunoGen. "While our product candidates to date have used DM1 as the effector molecule, this new class of taxane-based effector molecules...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-12-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry